Failure of reflux inhibitors in clinical trials: Bad drugs or wrong patients?

Gut

Volumn 61, Issue 10, 2012, Pages 1501-1509

  Kahrilas, Peter J ^a   Boeckxstaens, Guy ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; ADX 10059; ARBACLOFEN; ARBACLOFEN PLACARBIL; AZD 2066; AZD 9343; BACLOFEN; LESOGABERAN; METABOTROPIC RECEPTOR ANTAGONIST; PLACEBO; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG;

ADD ON THERAPY; DRUG EFFICACY; DRUG POTENCY; DRUG TREATMENT FAILURE; DYSPEPSIA; FATIGUE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; LOWER ESOPHAGUS SPHINCTER; NAUSEA; NONHUMAN; PARESTHESIA; PATHOPHYSIOLOGY; PATIENT IDENTIFICATION; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; STOMACH ACID SECRETION; SYMPTOM; THORAX PAIN;

GABA-B RECEPTOR AGONISTS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; HUMANS; PATIENT SELECTION; PROTON PUMP INHIBITORS; RECEPTORS, METABOTROPIC GLUTAMATE; TREATMENT FAILURE;

EID: 84866128073     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-301898     Document Type: Review

References (77)

1. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101:1900-20.
2. Wienbeck M, Barnert J. Epidemiology of reflux disease and reflux esophagitis. Scand J Gastroenterol Suppl 1989;156:7-13.
3. Jones MP, Sloan SS, Rabine JC, et al. Hiatal hernia size is the dominant determinant of esophagitis presence and severity in gastroesophageal reflux disease. Am J Gastroenterol 2001;96:1711-17.
4. Lin S, Ke M, Xu J, et al. Impaired esophageal emptying in reflux disease. Amer J Gastroenterol 1994;89:1003-6.
5. Gillen P, Keeling P, Byrne PJ, et al. Barrett's oesophagus: pH profile. Br J Surg 1987;74:774-6.
6. Singh P, Adamopoulos A, Taylor RH, et al. Oesophageal motor function before and after healing of oesophagitis. Gut 1992;33:1590-6.
7. Mittal RK, Lange RC, McCallum RW. Identification and mechanism of delayed esophageal acid clearance in subjects with hiatus hernia. Gastroenterology 1987;92:130-5.
8. Sloan S, Kahrilas PJ. Impairment of esophageal emptying with hiatal hernia. Gastroenterology 1991;100:596-605.
9. Vela MF, Craft BM, Sharma N, et al. Refractory Heartburn: comparison of intercellular space diameter in documented GERD vs. functional heartburn. Am J Gastroenterol 2011;106:844-50.
10. Kahrilas PJ, Shaheen NJ, Vaezi M; in collaboration with the AGAI Medical Position Panel on GERD management. AGAI medical position statement: management of gastroesophageal reflux disease. Gastroenterology 2008;135:1383-91.
11. Smith JA, Decalmer S, Kelsall A, et al. Acoustic cough-reflux associations in chronic cough: potential triggers and mechanisms. Gastroenterology 2010;139:754-62.
12. Clouse RE, Lustman PJ. Use of psychopharmacological agents for functional gastrointestinal disorders. Gut 2005;54:1332-41.
13. Vaezi MF, Richter JE, Stasney CR, et al. Treatment of chronic posterior laryngitis with esomeprazole. Laryngoscope 2006;116:254-60.
14. Kahrilas PJ, Howden CW, Hughes N. Response of regurgitation to proton pump inhibitor treatment in clinical trials of gastroesophageal reflux disease. Am J Gastroenterol 2011;106:1419-25.
15. Kahrilas PJ, Jonsson A, Denison H, et al. Responsiveness of regurgitation to potent acid suppression. Clin Gastroentrol Hepatol. Published Online First: 14 February 2012.
16. Kahrilas PJ, Hughes N, Howden CW. Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease. Gut 2011;60:1473-8.
17. Chang AB, Lasserson TJ, Gaffney J, et al. Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults. Cochrane Database Syst Rev 2011;(1):CD004823.
18. Holloway RH, Penagini R, Ireland AC. Criteria for objective definition of transient lower esophageal sphincter relaxation. Am J Physiol 1995;268:G128-33.
19. Mittal RK, Holloway RH, Penagini R, et al. Transient lower esophageal sphincter relaxation. Gastroenterology 1995;109:601-10.
20. Martin CJ, Dodds WJ, Liem HH, et al. Diaphragmatic contribution to gastroesophageal competence and reflux in dogs. Am J Physiol 1992;263:G551-7.
21. Pandolfino JE, Zhang Q, Ghosh SK, et al. tLESRs and reflux: mechanistic analysis using concurrent fluoroscopy and high-resolution manometry. Gastroenterology 2006;131:1725-33.
22. Martin CJ, Patrikios J, Dent J. Abolition of gas reflux and transient lower esophageal sphincter relaxation by vagal blockade in the dog. Gastroenterology 1986;91:890-6.
23. Dent J, Dodds WJ, Friedman RH, et al. Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. J Clin Invest 1980;65:256-67.
24. Goyal RK, Rattan S. Genesis of basal sphincter pressure: effect of tetrodotoxin on lower esophageal sphincter pressure in opossum in vivo. Gastroenterology 1976;71:62-7.
25. De Troyer A, Sampson M, Sigrist S, et al. Action of costal and crural parts of the diaphragm on the rib cage in dog. J Appl Physiol 1982;53:30-9.
26. Altschuler SM, Boyle JT, Nixon TE, et al. Simultaneous reflex inhibition of lower esophageal sphincter and crural diaphragm in cats. Am J Physiol 1985;249:G586-91.
27. Dodds WJ, Kahrilas PJ, Dent J, et al. Analysis of spontaneous gastroesophageal reflux and esophageal acid clearance in patients with reflux esophagitis. J Gastrointest Motil 1990;2:79.
28. van Herwaarden MA, Samsom M, Smout AJ. Excess gastroesophageal reflux in patients with hiatus hernia is caused by mechanisms other than transient LES relaxations. Gastroenterology 2000;119:1439-46.
29. Pandolfino JE, Bianchi LK, Lee TJ, et al. Esophagogastric junction morphology predicts susceptibility to exercise-induced reflux. Am J Gastroenterol 2004;99:1430-6.
30. Sloan S, Rademaker AW, Kahrilas PJ. Determinants of gastroesophageal junction incompetence: hiatal hernia, lower esophageal sphincter, or both? Ann Intern Med 1992;117:977-82.
31. Bredenoord AJ, Weusten BL, Timmer R, et al. Intermittent spatial separation of diaphragm and lower esophageal sphincter favors acidic and weakly acidic reflux. Gastroenteroogy 2006;130:334-40.
32. Wyman JB, Dent J, Heddle R, et al. Control of belching by the lower oesophageal sphincter. Gut 1990;31:639-46.
33. Sifrim D, Holloway R. Transient lower esophageal sphincter relaxations: how many or how harmful? Am J Gastroenterol 2001;96:2529-32.
34. Kwiatek KA, Post J, Pandolfino JE, et al. Transient lower esophageal sphincter relaxation in achalasia: everything but LES relaxation. Neurogastroenterol Mot 2009;21:1250-5.
35. Kahrilas PJ, Shi G, Manka M, et al. Increased frequency of transient lower esophageal sphincter relaxation induced by gastric distention in reflux patients with hiatal hernia. Gastroenterology 2000;118:688-95.
36. Zagorodnyuk VP, Chen BN, Brookes SJ. Intraganglionic laminar endings are mechano-transduction sites of vagal tension receptors in the guinea-pig stomach. J Physiol 2001;534:255-68.
37. Zagorodnyuk VP, Chen BN, Costa M, et al. Mechanotransduction by intraganglionic laminar endings of vagal tension receptors in the guinea-pig oesophagus. J Physiol 2003;553:575-87.
38. Beaumont H, Bennink RJ, de Jong J, et al. The position of the acid pocket as a major risk factor for acidic reflux in healthy subjects and patients with GORD. Gut 2010;59:441-51.
39. Pandolfino JE, Shi G, Trueworthy B, et al. Esophagogastric junction opening during relaxation distinguishes non-hernia reflux patients, hernia patients and normals. Gastroenterology 2003;125:1018-24.
40. Pandolfino JE, Shi G, Curry J, et al. Esophagogastric junction distensibility: a factor contributing to sphincter incompetence. Am J Physiol 2002;282:G1052-8.
41. Pandolfino JE, Shi G, Zhang Q, et al. Measuring EGJ opening patterns using high resolution intraluminal impedance. Neurogastroenterol Mot 2005;17:200-6.
42. Pandolfino JE, Zhang Q, Ghosh SK, et al. Upper sphincter function during transient lower esophageal sphincter relaxation (tLESR); it's mainly about microburps. Neurogastroenterol Mot 2007;19:203-10.
43. Pandolfino JE, El-Serag H, Zhang Q, et al. Obesity: a challenge to esophagogastric junction integrity. Gastroenterology 2006;130:639-49.
44. Zerbib F, Duriez A, Roman S, et al. Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors. Gut 2008;57:156-60.
45. Mittal RK, Holloway R, Dent J. Effect of atropine on the frequency of reflux and transient lower esophageal sphincter relaxation in normal subjects. Gastroenterology 1995;109:1547-54.
46. Hirsch DP, Tytgat GN, Boeckxstaens GE. Transient lower oesophageal sphincter relaxations - a pharmacological target for gastrooesophageal reflux disease? Aliment Pharmacol Ther 2002;16:17-26.
47. B receptors as drug targets to treat gastroesophageal reflux disease. Pharmacol Ther 2009;122:239-45.
48. B receptor agonism as a novel therapeutic modality in the treatment of gastroesophageal reflux disease. Adv Pharmacol 2010;58:287-313.
49. B agonist baclofen in normal subjects. Gastroenterology 2000;118:7-13.
50. Zhang Q, Lehmann A, Rigda R, et al. Control of transient lower oesophageal sphincter relaxations and reflux by the GABAB agonist baclofen in patients with gastro-oesophageal reflux disease. Gut 2002;50:19-24.
51. van Herwaarden MA, Samsom M, Rydholm H, et al. The effect of baclofen on gastro-oesophageal reflux, lower oesophageal sphincter function and reflux symptoms in patients with reflux disease. Aliment Pharmacol Ther 2002;16:1655-62.
52. Vela MF, Tutuian R, Katz PO, et al. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003;17:243-51.
53. B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. Gut 2003;52:464-70.
54. Beaumont H, Boeckxstaens GE. Does the presence of a hiatal hernia affect the efficacy of the reflux inhibitor baclofen during addon therapy? Am J Gastroenterol 2009;104:1764-71.
55. Boeckxstaens GE, Smout A. Systematic review: role of acid, weakly acidic and weakly alkaline reflux in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2010;32:334-43.
56. Cossentino MJ, Mann K, Armbruster SP, et al. Randomised clinical trial: the effect of baclofen in patients with gastro-oesophageal reflux - a randomised prospective study. Aliment Pharmacol Ther. Published Online First: 20 March 2012. doi:10.1111/j.1365-2036.2012.05068.x
57. Orr WC, Goodrich S, Wright S, et al. The effect of baclofen on nocturnal gastroesophageal reflux and measures of sleep quality: a randomized, cross-over trial. Neurogastroenterol Motil 2012;24:553e-253.
58. B receptor agonist, inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action. J Pharmacol Exp Ther 2009;331:504-12.
59. B receptor agonist lesogaberan (AZD3355) inhibits acid reflux and reduces esophageal acid exposure as measured with 24-h pHmetry in dogs. Eur J Pharmacol 2010;634:138-41.
60. Lal R, Sukbuntherng J, Tai EH, et al. Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism and elimination properties compared with R-baclofen. J Pharmacol Exp Ther 2009;330:911-21.
61. Boeckxstaens GE, Rydholm H, Lei A, et al. Effect of lesogaberan, a novel GABA(B)-receptor agonist, on transient lower oesophageal sphincter relaxations in male subjects. Aliment Pharmacol Ther 2010;31:1208-17.
62. Beaumont H, Smout A, Aanen M, et al. The GABA(B) receptor agonist AZD9343 inhibits transient lower oesophageal sphincter relaxations and acid reflux in healthy volunteers: a phase I study. Aliment Pharmacol Ther 2009;30:937-46.
63. Frisby CL, Mattsson JP, Jensen JM, et al. Inhibition of transient lower esophageal sphincter relaxation and gastroesophageal reflux by metabotropic glutamate receptor ligands. Gastroenterology 2005;129:995-1004.
64. Jensen J, Lehmann A, Uvebrant A, et al. Transient lower esophageal sphincter relaxations in dogs are inhibited by a metabotropic glutamate receptor 5 antagonist. Eur J Pharmacol 2005;519:154-7.
65. Rohof WO, Lei A, Hirsch DP, et al. The effects of a novel metabotropic glutamate receptor 5 antagonist (AZD2066) on transient lower oesophageal sphincter relaxations and reflux episodes in healthy volunteers. Aliment Pharmacol Ther 2012;35:1231-42.
66. Zerbib F, Keywood C, Strabach G. Efficacy, tolerability and pharmacokinetics of a modified release formulation of ADX10059, a negative allosteric modulator of metabotropic glutamate receptor 5: an esophageal pH-impedance study in healthy subjects. Neurogastroenterol Motil 2010;22:859-65, e231.
67. Shaw MJ, Talley NJ, Beebe TJ, et al. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol 2001;96:52-7.
68. Boeckxstaens GE, Beaumont H, Hatlebakk JG, et al. A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial. Gut 2011;60:1182-8.
69. Shaheen NJ, Denison H, Björck K, et al. Efficacy of a novel γ-aminobutyric acid type B receptor (GABAB) agonist, lesogaberan, as an add-on to proton pump inhibitor (PPI) therapy in the treatment of gastroesophageal reflux disease in patients who have a partial response to PPI therapy. Gastroenterology 2011;140 (5 Suppl 1):S-580.
70. Shaheen NJ, Denison H, Björck K, et al. Safety profile of a novel γ-aminobutyric acid type B receptor (GABAB) agonist, lesogaberan, as an add-on to proton pump inhibitor (PPI) therapy in the treatment of gastroesophageal reflux disease in patients who have a partial response to PPI therapy. Gastroenterology 2011;140(5 Suppl 1):S-577.
71. Gerson LB, Huff FJ, Hila A, et al. Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophagal reflux disease. Am J Gastroenterol 2010;105:1266-75.
72. Vakil NB, Huff FJ, Bian A, et al. Arbaclofen placarbil in GERD: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol 2011;106:1427-38.
73. Keywood C, Wakefield M, Tack J. A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease. Gut 2009;58:1192-9.
74. Zerbib F, Bruley des Varannes S, Roman S, et al. Randomised clinical trial: effects of monotherapy with ADX10059, a mGluR5 inhibitor, on symptoms and reflux events in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2011;33:911-21.
75. Castell DO, Zerbib F, Bruley Des Varannes S, et al. Efficacy and tolerability of ADX10059, a mGluR5 negative allosteric modulator, as add on therapy to proton pump inhibitors (PPIs) in patients with gastroesophageal reflux disease (GERD). Gastroenterology 2011;140:S-577.
76. http://clinicaltrials.gov/ct2/show/NCT00820105
77. Zerbib F, Roman S, Ropert A, et al. Esophageal pH - impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 2006;101:1956-63.